Peñaloza CM

Language: Spanish
References: 19
Page: 91-101
PDF size: 346.20 Kb.

ABSTRACT

Background: Acuphen is a common symptom that requires a wide study protocol to identify possible treatment to causes. Most of them are due to nerve receptors injury anywhere in the auditory tract because of multiple etiologies, and with difficult therapy.
Objective: To determine utility of intratimpanic corticosteroids treatment in multiple etiology acuphen.
Patients and Method: Thirty-five patients older than 18 years with more than a month of acuphen as main symptom, idiopathic or secondary to sudden hypoacusis, endolymphatic hydrops, vascular or metabolic cortiphaty, presbiacusis or acustic trauma. Patients with otitis media, surgery or otitic neoplasia were excluded.
Results: Twenty-seven patients (77.1%) of 35 have 10 to 80% improvement, only eight (22.8%) haven’t it, and none get worse. Seventy-three percent with betamethasone phosphate/dipropionate and 88% dexamethasone phosphate therapies have improvement.
Conclusions: Intratimpanic corticosteroids are an alternative therapy to avoid systemic side effects. They have the advantages of in-office administration, patient resistance and no complications. Further investigation to determine long term procedure effects, ideal drug, optimal dose and administration technique with best results and less complications is needed.

REFERENCES

1. Seidman M, Jacobson G. Update on tinnitus. Otolaryngol Clin North Am 1996;29(3):455-65.

2. Courtney N, Meyerhoff W. Diagnosis and treatment of this elusive symptom. Geriatrics 2003;58(2):28-34.

3. Jackler R, Brackmann D. Neurotology. 1st ed. St Louis Missouri: Mosby, 1994;pp:153-66.

4. Lockwood A, et al. Current concepts: tinnitus. NEJM 2002;347(12):904-10.

5. Dobie R. A review of randomized clinical trials in tinnitus. Laryngoscope 1999;109:1202-9.

6. Silverstein H, et al. Intratympanic steroid treatment of inner ear disease and tinnitus (preliminary report). Ear Nose Throat J 1996;75(8):468-88.

7. Nordang L, Linder B. Morphologic changes in round window membrane after topical hidrocortisone and dexamethasone treatment. Otol Neurotol 2003;24(2):339-43.

8. Doyle K, et al. Intratympanic steroid treatment: a review. Otol Neurotol 2004;25(6):1034-9.

9. Silverstein H, et al. Innear ear perfusion and the role of round window patency. Am J Otol 1997;18(5):586-9.

10. Bar rs D, et al. Int ratympanic steroid injections for intractable Meniere’s disease. Laryngoscope 2001;111(12):2100-4.

11. Nadel D. The use of systemic steroids in otolaryngology. Ear Nose Throat J 1996;75(8):504-16.

12. Shirwany N, Seidman M. Effect of transtympanic injection of steroid on cochlear blood flow. Auditory sensitivity, and histology in Guinea pig. Am J Otol 1998;19(2):230-5.

13. Rarey K, Curtis L. Receptors for glucocorticoids in the human inner ear. Otolaryngol Head Neck Surg 1996;115:38-41.

14. Chandrasekhar S. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22(1):18-23.

15. Silverstein H, et al. Dexamethasone inner ear perfusion for the treatment of Meniere’s disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998;19(2):196-201.

16. Parnes L, et al. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical aplication. Laryngoscope 1999, 109:1-17.

17. Becvariovski Z, et al. Round window gentamicin absorption: an in vivo human model. Laryngoscope 2002;112(9):1610-13.

18. Gianoli G, et al. Transtympanic steroid for treatment of sudden hearing loss. Otolaryngol Head Neck Surg 2001;125:142-6.

19. Sennaroglu L, et al. Intratympanic dexamethasone, intratympanic gentamicin and sac surgery for intractable vertigo in Meniere’s disease. Otolaryngol Head Neck Surg 1998;125(5):537-43.